PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients

ConclusionsThe convergent and criterion validity of the PROMIS depression measures in cancer populations was confirmed, although the optimal cut-off points are not established. PROMIS measures were briefer than BDI-II and CES-D but do not offer any advance in terms of diagnostic accuracy, reduced response burden or cost over other legacy measures of depression in oncology patients.
Source: Quality of Life Research - Category: Health Management Source Type: research